Immunome Inc Stock Price, News & Analysis

Immunome (Nasdaq: IMNM) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.

Interested parties can access a live audio webcast via the company Investor Relations website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.

Immunome (Nasdaq: IMNM) priced an underwritten public offering of 18,625,000 shares of common stock at $21.50 per share, with gross proceeds to the company of approximately $400 million. The underwriters have a 30-day option to purchase up to an additional 2,793,750 shares at the public offering price (the 15% overallotment).

The offering is expected to close on December 18, 2025, subject to customary closing conditions. Joint bookrunners include Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities.

Immunome (Nasdaq: IMNM) announced a proposed underwritten public offering of $400 million of common stock, with Immunome offering all shares and a 30-day underwriter option to purchase up to an additional $60 million.

The offering is subject to market and other conditions and may not be completed as proposed. Joint bookrunning managers are Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities; co-leads are Wedbush PacGrow and LifeSci Capital. The offering will be made from a Form S-3 shelf registration that became effective on February 13, 2024, and a preliminary prospectus supplement will be filed with the SEC.

Immunome (Nasdaq: IMNM) reported positive topline Phase 3 RINGSIDE results for oral varegacestat in progressing desmoid tumors. The trial met the primary endpoint with a progression-free survival HR = 0.16 (84% risk reduction; 95% CI: 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% vs. 9% for placebo (p<0.0001). Exploratory median best tumor volume change was -83% vs. +11% for placebo. Key secondary endpoints, including landmark tumor reduction and worst pain, were met. Varegacestat was generally well tolerated; common AEs included diarrhea (82%), fatigue (44%) and rash (43%). NDA planned for Q2 2026.

Immunome (Nasdaq: IMNM) will disclose topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors on Monday, December 15, 2025.

The company will host a live webcast and conference call on December 15, 2025 at 8:30 a.m. ET (5:30 a.m. PT) that includes presentation slides and a live Q&A following prepared remarks. The webcast is listen-only; questions must be asked via the conference call. The webcast will be archived on Immunome's investor website for 90 days.

Immunome (Nasdaq: IMNM) announced that on December 1, 2025 its Compensation Committee granted inducement non‑statutory stock options to four new employees totaling 88,000 shares under the Company’s 2024 Inducement Plan.

Each option has an exercise price of $18.32 per share (the company’s closing price on December 1, 2025) and vests over four years: 25% at the one‑year anniversary and the remainder monthly over the following 36 months, subject to continued service and the plan and option agreement terms.

Immunome (Nasdaq: IMNM) said members of management will present at two investor conferences on December 3, 2025. Presentations and times: Piper Sandler 37th Annual Healthcare Conference at 9:00 a.m. ET and Evercore 8th Annual Healthcare Conference at 9:10 a.m. ET. Interested parties can listen via live audio webcasts on the company’s Investor Relations website at www.immunome.com. Replay webcasts will be available for approximately 30 days after each live presentation.

Immunome (Nasdaq: IMNM) reported third quarter 2025 results and a program update on November 6, 2025. Cash and cash equivalents were $272.6 million as of September 30, 2025, including $44.9 million net proceeds from its at-the-market equity offering; the company expects this cash to fund operations into 2027.

Clinical highlights: topline data for the Phase 3 RINGSIDE Part B study of varegacestat is expected before end of 2025; objective responses were observed at multiple dose levels in B-cell lymphoma patients treated with IM-1021, with initial IM-1021 data planned for 2026. IND clearance for IM-3050 was received in April 2025.

Quarterly expenses included R&D of $49.2 million and G&A of $10.9 million; net loss was $57.5 million.

Immunome (Nasdaq: IMNM) announced that on Nov. 3, 2025 its Compensation Committee granted inducement stock options to three new employees under the company’s 2024 Inducement Plan.

The grants total 19,000 nonstatutory stock options with an exercise price of $17.00 per share (the company’s closing price on Nov. 3, 2025). The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and the remainder vesting monthly over the following 36 months, subject to continued service, and are governed by the 2024 Inducement Plan and individual option agreements.

The Compensation Committee approved the awards as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).